Non-muscle-invasive Bladder Cancer

Intravesical BCG vs GEMDOCE in NMIBC

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Effects of Microbiological and Immunological Factors on the Lower Urinary Tract

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

A Phase I Intravesical PPM Therapy for NMIBC

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer

T-Control® Safety for Cytostatics Management

Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)

LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer